Some way off first sales though. Clinical trials, reg process etc to be completed etc. all costs borne by this new distribution partner.
what I am having trouble getting my head around is that this company like others are picking up all or most of the upfront approval costs. Now I don't think they're doing that for zero. The margins for MVP must be squeezed considerably. I am guessing. Would like someone to explain how this works.
When it comes to distribution these guys drive hard bargains unless there's competitive tension.
Ann: Penthrox Licensing Deal for Russia, page-3
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
0.055(13.6%) |
Mkt cap ! $51.82M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 46.0¢ | 42.5¢ | $34.05K | 77.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1575 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 2156 | 1 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| MVP (ASX) Chart |